Cover Image
市場調查報告書

天花:開發平台分析

Smallpox - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 192826
出版日期 內容資訊 英文 84 Pages
訂單完成後即時交付
價格
Back to Top
天花:開發平台分析 Smallpox - Pipeline Review, H2 2016
出版日期: 2016年07月13日 內容資訊: 英文 84 Pages
簡介

所謂天花是因天花病毒造成的急性接觸感染症。主要的症狀有發熱、不舒服、頭痛、極度疲勞、激烈背痛、腹痛及嘔吐等。之後還會在臉、手、前臂及軀體產生皮疹。此外口、鼻黏膜也會產生病斑。潰瘍性的病斑會在口、喉嚨中放出大量病毒。

本報告提供天花治療藥的開發情形調查分析,提供您開發中產品概要,臨床實驗的各階段產品概要,主要企業簡介,藥物簡介,開發中產品的最新趨勢,最新消息和新聞稿等相關的系統性資訊。

目錄

簡介

天花概要

治療藥的開發

  • 開發中產品:概要
  • 開發中產品:比較分析

開發中的治療藥:各企業

開發中產品概要

  • 後期階段的產品
  • 初期階段的產品
  • 未確認階段的產品

開發中的產品:各企業

開發中的產品:大學/研究機關別

開發治療藥的企業

  • Bavarian Nordic A/S
  • CEL-SCI Corporation
  • Chimerix, Inc.
  • EpiVax, Inc.
  • Nanotherapeutics, Inc.
  • Oncovir, Inc.
  • SIGA Technologies, Inc.
  • Symphogen A/S
  • TapImmune Inc.
  • Tonix Pharmaceuticals Holding Corp.

治療藥的評估

  • 單獨療法的情況
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介(產品說明·作用機制·R&D進展)

  • 24a
  • brincidofovir
  • CEL-1000
  • cidofovir
  • imatinib mesylate
  • Monoclonal Antibodies for Infectious Disease
  • PL-801
  • Poly-ICLC
  • small pox vaccine
  • smallpox vaccine
  • smallpox vaccine
  • Sym-002
  • tecovirimat
  • TPIV-300
  • VIR-002

開發中產品的最新趨勢

暫停的計劃

開發中止的產品

產品開發的里程碑

  • 最新消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8275IDB

Summary

Global Markets Direct's, 'Smallpox - Pipeline Review, H2 2016', provides an overview of the Smallpox pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Smallpox, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Smallpox and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Smallpox
  • The report reviews pipeline therapeutics for Smallpox by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Smallpox therapeutics and enlists all their major and minor projects
  • The report assesses Smallpox therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Smallpox

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Smallpox
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Smallpox pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Smallpox Overview
  • Therapeutics Development
    • Pipeline Products for Smallpox - Overview
    • Pipeline Products for Smallpox - Comparative Analysis
  • Smallpox - Therapeutics under Development by Companies
  • Smallpox - Therapeutics under Investigation by Universities/Institutes
  • Smallpox - Pipeline Products Glance
    • Late Stage Products
    • Early Stage Products
  • Smallpox - Products under Development by Companies
  • Smallpox - Products under Investigation by Universities/Institutes
  • Smallpox - Companies Involved in Therapeutics Development
    • Bavarian Nordic A/S
    • BioFactura, Inc.
    • CEL-SCI Corporation
    • Chimerix, Inc.
    • CJ HealthCare Corp.
    • EpiVax, Inc.
    • SIGA Technologies, Inc.
    • Takeda Pharmaceutical Company Limited
    • Tonix Pharmaceuticals Holding Corp.
  • Smallpox - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Combination Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • (plague + small pox) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • 24a - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • brincidofovir - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CEL-1000 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CJ-40011 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • imatinib mesylate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Monoclonal Antibodies for Infectious Disease - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Monoclonal Antibody for Smallpox - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • nilotinib - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PL-801 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SCV-305 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • small pox vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • smallpox vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • smallpox vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • tecovirimat - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • VIR-002 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Smallpox - Dormant Projects
  • Smallpox - Discontinued Products
  • Smallpox - Product Development Milestones
    • Featured News & Press Releases
      • Jun 15, 2016: Bavarian Nordic Announces Expansion of IMVAMUNE Orders from Canadian Government
      • Feb 24, 2016: FDA Concurs on Clinical Dose for SIGA's Tecovirimat Antiviral
      • Feb 08, 2016: Chimerix Presents Positive Results From Brincidofovir Pivotal Study in Animal Model for Smallpox
      • Dec 24, 2015: Delaware Supreme Court Affirms Chancery Court Ruling in Favor of PharmAthene
      • Sep 14, 2015: Chimerix and BARDA Announce Contract Extension of $13.0 Million for the Continued Development of Brincidofovir for Smallpox
      • Jul 23, 2015: Chimerix Announces Positive Topline Results From Brincidofovir Pivotal Study in Animal Model for Smallpox
      • Jul 07, 2015: Bavarian Nordic Receives Order for IMVAMUNE Smallpox Vaccine from the U.S. Government Valued at USD 133 Million
      • May 13, 2015: Bavarian Nordic Announces Positive Results from Two Pivotal Clinical Studies of IMVAMUNE Smallpox Vaccine
      • Jan 16, 2015: SIGA Technologies Appeals Judgment of Delaware Court of Chancery
      • Jan 07, 2015: Delaware Court of Chancery Issues Order Specifying Amount Of Lump Sum Expectation Damages Payable To PharmAthene; Total Award When Finalized, Including Pre-Judgment Interest, Attorneys' And Expert Witness Fees, Estimated To Be In Excess Of $190 Million
      • Dec 23, 2014: Chimerix Provides Recap of 2014 Events
      • Oct 04, 2014: Bavarian Nordic Announces Exercise of Contract Option by the U.S. Government for Continued Supply of IMVAMUNE Smallpox Vaccine
      • Sep 04, 2014: Bavarian Nordic Announces Exercise Of Contract Option By The U.S. Government For Continued Supply Of Imvamune Smallpox Vaccine
      • Sep 02, 2014: Chimerix and BARDA Announce Continued Partnership in the Development of Brincidofovir for Smallpox
      • Aug 26, 2014: Bavarian Nordic Receives Order from the Canadian Government to Supply IMVAMUNE Smallpox Vaccine
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Smallpox, H2 2016
  • Number of Products under Development for Smallpox - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Investigation by Universities/Institutes, H2 2016
  • Smallpox - Pipeline by Bavarian Nordic A/S, H2 2016
  • Smallpox - Pipeline by BioFactura, Inc., H2 2016
  • Smallpox - Pipeline by CEL-SCI Corporation, H2 2016
  • Smallpox - Pipeline by Chimerix, Inc., H2 2016
  • Smallpox - Pipeline by CJ HealthCare Corp., H2 2016
  • Smallpox - Pipeline by EpiVax, Inc., H2 2016
  • Smallpox - Pipeline by SIGA Technologies, Inc., H2 2016
  • Smallpox - Pipeline by Takeda Pharmaceutical Company Limited, H2 2016
  • Smallpox - Pipeline by Tonix Pharmaceuticals Holding Corp., H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Assessment by Combination Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Smallpox - Dormant Projects, H2 2016
  • Smallpox - Dormant Projects (Contd..1), H2 2016
  • Smallpox - Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for Smallpox, H2 2016
  • Number of Products under Development for Smallpox - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Targets, H2 2016
  • Number of Products by Stage and Targets, H2 2016
  • Number of Products by Mechanism of Actions, H2 2016
  • Number of Products by Stage and Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top